PMID- 29137718 OWN - NLM STAT- MEDLINE DCOM- 20180709 LR - 20181202 IS - 1879-0070 (Electronic) IS - 0732-8893 (Linking) VI - 89 IP - 4 DP - 2017 Dec TI - Telavancin for the treatment of methicillin-resistant Staphylococcus aureus bone and joint infections. PG - 294-299 LID - S0732-8893(17)30278-X [pii] LID - 10.1016/j.diagmicrobio.2017.09.004 [doi] AB - This retrospective, case series describes our experience with the use of telavancin in patients with methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis and prosthetic joint infection. The primary objectives were clinical outcomes and adverse events (AEs), and a secondary outcome described microbiological susceptibility. Fourteen patients were enrolled. Median duration of therapy was 58 days, and four patients had concurrent bacteremia. End-of-treatment outcomes were available in 78% of patients, with a clinical success rate of 91%. Thirty-day and 12-month outcomes were also obtained. Seven patients experienced AEs. Infusion-related reactions were most common, and three AEs required discontinuation of therapy. All MRSA isolates had a telavancin MIC